Whalesbook
Trial Success Amid Regulatory Questions
Eli Lilly's oral weight-loss drug Foundayo showed positive results in a recent trial, confirming its cardiovascular safety and a significant reduction in death risk. However, this success is tempered by U.S. Food and Drug Administration (FDA) requests for more safety assurances. This regulatory step adds complexity for investors assessing Foundayo's future and Eli Lilly's high stock valuation.
Key Trial Findings and FDA Data Request
Foundayo proved to be no worse than older insulin treatments at preventing major heart problems over two years. The trial also showed a 57% lower risk of death from any cause for patients taking Foundayo compared to insulin, though more statistical review is needed. The FDA has now requested further clinical trials by July to closely examine risks of drug-induced liver injury (DILI) and major adverse cardiovascular events (MACE). Requiring full clinical trials, not just observational studies, for these specific concerns signals a cautious regulatory approach, especially after Foundayo received expedited review. Eli Lilly shares rose in pre-market trading after the trial results were announced, although the stock is down 16% year-to-date.
Valuation and Competition in the Obesity Market
Eli Lilly's stock carries a high valuation, with a Price-to-Earnings (P/E) ratio around 39-41x, significantly higher than competitor Novo Nordisk's P/E of 10-11x. This gap indicates investors expect strong future growth from Lilly's weight-loss and diabetes drugs. The global market for obesity drugs is expected to grow substantially, potentially reaching $82-$98 billion by 2032-2033, fueled by GLP-1 drugs. Foundayo's oral format is an advantage, but it faces stiff competition. Novo Nordisk's Wegovy (semaglutide) already has approvals for reducing cardiovascular risk and has shown benefits in real-world studies compared to Lilly's Zepbound (tirzepatide). Lilly's tirzepatide has shown significant reductions in heart failure and hospitalizations in trials, demonstrating Lilly's capabilities in this field. However, the regulatory questions surrounding Foundayo, combined with Lilly's high valuation, put the company under close investor watch.
Regulatory Hurdles and Investor Concerns
The FDA's requirement for clinical trials on MACE and DILI for Foundayo, plus concerns about stomach contents and risks during breastfeeding, pose significant challenges. These demands suggest the FDA believes initial data might not fully address serious safety risks, pushing some risk assessment to after approval. This creates uncertainty for Foundayo, particularly amid fierce competition. Novo Nordisk's established Wegovy drug has shown cardiovascular benefits and has approvals Lilly's Zepbound does not yet hold. Some real-world data even suggests Wegovy may offer greater cardiovascular risk reduction than Zepbound in certain patients. Lilly's high valuation means the stock could fall sharply if there are regulatory delays or safety problems. Analysts remain largely positive with high price targets, but the company's valuation leaves little room for setbacks.
Analyst Outlook and Future Plans
Despite these regulatory steps, Wall Street analysts largely maintain 'Buy' or 'Strong Buy' ratings for Eli Lilly. Average price targets suggest a potential upside of 30-39%, showing confidence in Lilly's growth plans and its strong position in obesity and diabetes drugs. Lilly is focused on growing its GLP-1 offerings, with plans to submit Foundayo for type 2 diabetes approval by the end of the second quarter. This strategy, along with the booming obesity drug market, fuels analyst optimism. However, successfully meeting post-marketing regulatory demands will be key for the company to achieve its full potential.